
    
      This is an open-label, international, Phase 3 study evaluating the efficacy and safety of the
      S-1/cisplatin regimen versus the 5-FU/cisplatin regimen in chemotherapy-na√Øve patients with
      metastatic diffuse gastric carcinoma including carcinoma of the gastro-esophageal junction.
      Patients will be randomly assigned to S-1/cisplatin (experimental regimen, Arm A) or
      5-FU/cisplatin (control regimen, Arm B).
    
  